Successful allo‐hematopoietic stem cell transplantation using washed hematopoietic stem cells in a pediatric patient complicated by acute myeloid leukemia and severe anaphylaxis to blood product Authors: Jieyu Tian, Guanghua Zhu, Maoquan Qin, Chenguang Jia, Shuxuan Ma, Bin Wang, Yanhui Luo Published: 2026 To the Editor: Leukemia is a common life‐threatening hematological malignancy, the development of which has been associated with a range of etiological factors. Since immunosuppressive agents are used to treat inflammatory bowel disease (IBD), leukemias are often diagnosed in patients with this disease. 1 Hematopoietic stem cell transplantation (HSCT), an essential treatment for high‐risk leukemia, is critically dependent on transfusions. Severe allergic reactions to these transfusions can complicate and potentially derail the treatment process. This report presents the case of a child diagnosed with ulcerative colitis (UC) who developed acute myeloid leukemia (AML) during the course of anti‐inflammatory treatment and experienced significant allergic reactions to blood products. These complications required modification of the donor‐derived stem cells before their infusion during subsequent allogeneic HSCT (allo‐HSCT). When the patient was ten years old, she presented with recurrent abdominal pain, diarrhea, and mucopurulent bloody stools, and colonoscopies led to a diagnosis of UC. During the first 18 months of the illness, the child received combination therapy including hormones, mesalazine, azathioprine, cyclosporine, infliximab, and methotrexate, but the condition did not improve until she subsequently underwent 10 fecal bacterial transplantations. The patient developed multiple medication allergies during UC treatment, particularly severely allergic to blood products (Table S1). While total immunoglobulin E (IgE) levels remained normal, no family history of allergic diseases was reported, and the medical history was unremarkable except for UC. A comprehensive exon gene profile of 47, XXX revealed that only the GRCh/hg19 variant was associated with hyperfemininity. At the age of 15 years, during UC treatment, the patient developed severe pneumonia and hematological abnormalities. Bone marrow examination during pneumonia treatment revealed 80.5% morphologically immature cells. Immunophenotyping revealed the expression of CD34dim, CD117, CD13, CD33, CD38, CD64, and HLA‐DRbri. Chromosomal analysis revealed 47, XX, +X/47, idem.del(7) (q22), with FISH confirming the presence of monosomy 7 and del(7q), classifying the case as high risk of AML. In subsequent therapies, the patient experienced severe anaphylactic shock symptoms during infusion of red blood cells and platelets (Table S1). When the irradiated, washed, and leukocyte‐depleted red blood cells were tried, she was well‐tolerated with no anaphylaxis. However, after transfusion with irradiated, leukocyte‐depleted platelets, the patient experienced recurrence of anaphylactic symptoms. The patient was eligible for allo‐HSCT, and the donor was the patient's HLA‐matched (10/10) sister. The conditioning regimen consisted of azacitidine (75 mg/m2 × 7 days), fludarabine (30 mg/m2 × 5 days), busulfan (3.2 mg/kg/d × 3 days), cytarabine (4 g/m2 × 1 day), and cyclophosphamide (30 mg/kg/d × 4 days), with cyclosporine and methotrexate for graft‐versus‐host disease prophylaxis (Figure S1). On day –4 of conditioning, the patient received a transfusion of irradiated, leukocyte‐depleted platelets. Approximately five minutes post‐infusion, the patient experienced an anaphylactic reaction involving chest tightness, reduced transcutaneous oxygen saturation, cold extremities, and hypotension. The transfusion was immediately discontinued, and resuscitative measures were initiated. An emergency multidisciplinary team consultation was convened immediately, and it was found that the patient had an anaphylactic reaction to packed red blood cells but tolerated washed red blood cells, suggesting a hypersensitivity reaction directed primarily against plasma proteins. We assumed that saline‐washed platelets and donor‐derived hematopoietic stem cells could be processed prior to transfusion to reduce allergenic plasma proteins and enrich the infusion with sufficient autologous plasma to prevent cell clumping. The donor provided 282 mL of peripheral blood stem product containing 9.78×108 mononuclear cells (MNC)/kg and 11.52×106 CD34+ cells/kg. The washing solution was prepared using 10 mL of autologous plasma and 100 mL of saline. Given the patient's confirmed albumin allergy and the fact that albumin is required to mitigate cell aggregation and maintain osmotic stability, we opted to use autologous plasma. The collected stem cells were centrifuged to remove the plasma. Subsequently, 50 mL of washing solution was added to the cell fraction, followed by centrifugation. This washing procedure was repeated twice (Figure S2). Finally, we obtained 140 mL of processed cells containing 10.84×108 MNC/kg and 8.82×106 CD34+/kg, which is well above the widely accepted minimum requirement for successful engraftment but represents a 23% loss rate. Stem cell infusion was performed successfully. Subsequent transfusions using platelets washed with pure saline were completed without incident. Granulocyte and platelet engraftment occurred on day +11 and +12, respectively. No severe clinical complications were noted. Post‐transplant monitoring showed complete marrow remission, negative minimal residual disease, absence of monosomy 7, and complete donor chimerism. The UC remained well‐managed. Malignant hematological disorders, including leukemia, have been found to occur more frequently in patients with IBD than in the non‐IBD population. 2 In patients with IBD, the chronic inflammatory environment, the increasing use of biologics and immunosuppressive drugs, and persistent gut inflammation lead to immune dysregulation, which alters the levels of immune components. These alterations may subsequently dysregulate immune responses within the tumor microenvironment, increasing the risk of malignancy. 3 , 4 , 5 , 6 This patient developed refractory UC, which was unresponsive to multiple medication regimens, preceding the onset of AML. For refractory IBD, some studies recommend allo‐HSCT for durable remission. 7 Anaphylaxis is characterized by a rapid onset and multiple threatening symptoms mediated by IgE. Our patient experienced severe anaphylactic reactions induced by various blood products, biologics, and antibiotics throughout the disease course. Despite normal total IgE levels, the clinical presentation was consistent with a type I rapid‐onset hypersensitivity reaction, indicating IgE mediation. The possibility of aberrant mast cell activation should be considered in light of the multiple drug‐induced severe allergic reactions. Although no significant mutations, including the KIT D816V variant, were detected, the cause of the patient's severe allergic reactions could not be identified. 8 Allergic transfusion reactions (ATRs) represent a frequent complication of blood transfusion, particularly in platelet transfusions. 9 , 10 Our patient presented a complex case during the initial stages of treatment. Extensive evaluation and investigation revealed allergies to specific albumin and plasma components, rather than to red blood cells and platelets. Antihistamines appear to reduce the risk of anaphylactic reactions by relieving the symptoms of type I hypersensitivity. As demonstrated in several randomized controlled trials and cohort studies and confirmed by our findings, administration of antihistamines prior to the procedure did not prevent ATRs. 11 Many reports recommend plasma‐reduced/washed platelet concentrate as a prophylactic treatment against transfusion‐related adverse reactions. 12 , 13 Previous studies have demonstrated that the incidence of ATRs remains unaffected by the type of platelet additive solution or the specific washing method used. 12 Tanaka et al. 14 compared the use of regular with half‐volume resuspended platelet concentrate, revealing a significant difference in platelet recovery rates between the two groups (90.0% vs. 80.2%, P < 0.001), although the post‐transfusion corrected count increments were comparable. At our center, the loss of stem cells subjected to plasma removal is approximately 10%–20%, aligning with previous reports on washed platelets, and both are superior to the 23% loss observed during our stem cell washing procedure, which may be attributed to the additional centrifugation step employed. Human serum albumin (2%–5%) is routinely used for stem cell preservation, with a higher concentration required for umbilical cord blood stem cells. However, some studies have used a washing solution containing 0.5% albumin for short‐term storage. Given the patient's poor condition, we prepared a dedicated washing solution containing approximately 0.4% albumin by mixing 10 mL of the child's autologous plasma with 100 mL of normal saline, achieving a concentration close to 0.5%. The patient had a clear allergy to allogeneic albumin and blood products. Under urgent conditions with an unknown spectrum of potential allergens, resuspending the stem cells in the patient's own plasma and infusing them as soon as possible was the optimal strategy for stem cell protection. Given the lack of readily available comparable experience, the safety and efficacy of this protocol require confirmation in future studies. We shared our experience using saline‐washed hematopoietic stem cells and platelet transfusion. The development of this stem cell purification protocol may provide a critical foundation for the successful transplantation of patients with severe allergies to blood components. The UC also remained stable after transplantation, suggesting that HSCT could be a viable treatment for refractory IBD. CONSENT FOR PUBLICATION Written informed consent was obtained from the parents of the patients. CONFLICT OF INTEREST The authors declare no conflict of interest. Supporting information Supporting Information REFERENCES Associated Data Supplementary Materials Supporting Information